SafineAI's new type of microscope that uses a bowl studded with LED lights of various colors and lighting schemes produced by machine learning.

SafineAI

DUKE INVENTOR: Roark Horstmeyer
safineai.com

Basic blood tests require significant manual effort and are ubiquitous bottlenecks in healthcare systems. SafineAI seeks to develop a new “intelligent” computational microscope that, combined with cloud-based machine learning algorithms, will automate blood analysis and open up new diagnostic possibilities.

Duke engineering graduate students formed SafineAI to miniaturize a reconfigurable LED microscope. This concept has already earned them a $120,000 prize at a local pitch competition.

This microscope adapts its lighting angles, colors, and patterns while teaching itself the optimal settings needed to complete a given diagnostic task. In the initial proof-of-concept study, the microscope simultaneously developed a lighting pattern and classification system that allowed it to quickly identify red blood cells infected by the malaria parasite more accurately than trained physicians and other machine learning approaches.

The research was published in Biomedical Optics Express, a publication of The Optical Society (OSA) (www.dx.doi.org/10.1364/BOE.10.006351).

Simbuka

DUKE INVENTOR: Edgard Ngaboyamahina

simbuka.africa

Simbuka is a Social Enterprise registered in Rwanda that positions environmental technologies and solutions for private sector investment and scale through technology validation and identification of an appropriate business model. Simbuka develops and implements adequate pilot programs to ensure the required resources are available and demonstrate economic viability in Rwanda and across the continent. By leveraging existing non-government and government programs in environmental management, WaSH (Water, Sanitation, and Hygiene) and manufacturing, Simbuka identifies appropriate partners to integrate innovation into the wider socio-economic framework, thus safeguarding continuation beyond the initial deployment.

Simbuka is currently exploring pilot opportunities and business models for technologies developed by the Duke University Center for Water, Sanitation, Hygiene and Infectious Disease (WaSH-AID)North Carolina State University, and Triangle Environmental.

simbuka technological innovations logo
S.H.E. is a fully automated, sterile, sanitary pad disposal unit engineered to provide dignity and privacy, waste reduction and safe hygiene.
S.H.E. is a fully automated, sterile, sanitary pad disposal unit engineered to provide dignity and privacy, waste reduction and safe hygiene.

S.H.E. – Safe Hygiene for Everyone

Menstrual Hygiene and Health (MHH) is a neglected sanitation topic in emerging markets, and menstrual waste disposal is particularly absent in many shared and public settings. Waste streams are growing with increased urbanization and access to disposable products. Safe, discreet and compact disposal options, such as the S.H.E., can empower women and girls, support better health and a cleaner environment. S.H.E. is a fully automated, sterile, sanitary pad disposal unit engineered to provide dignity and privacy, waste reduction and safe hygiene. With a capacity of up to 15 pads at a time and a processing time under 15 minutes, S.H.E. thermally treats pads between 800 and 900°C, emitting virtually no smoke and producing minimal ash.  Center for WaSH-AIDBiomass Controls

Dr. Ngaboyamahina

NgaboyamahinaDr. Ngaboyamahina is the Founder and Managing Director of Simbuka. He’s also a Research Scientist at the Duke Center for WaSH-AID (Water, Sanitation, Hygiene and Infectious Disease) where he leads R&D activities that encompass waste treatment and technology transfer under the Bill & Melinda Gates Foundation-supported Reinvent the Toilet Challenge. The Center for WaSH-AID is an intensely collaborative translational research team, working closely with academic, non-profit, and private industry partners to facilitate the development and sustainable deployment of novel technology-based health solutions around the world.

Immcure

DUKE INVENTOR: Qi-Jing Li, Xiao-Fan Wang
immcure.com

Immcure aims to develop next-generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead to a cure.

immcure logo

Memory / Exhaustion resistant CAR-T / TCR-T therapy

Immcure’s unique T cell genetic engineering platform is geared to modify T cells for enhanced therapeutic potential, which includes memory T cell differentiation programs and exhaustion resistant T cell transformation programs. CAR-T and TCR-T products armed with such modifications can achieve prolonged cancer metastasis control as well as improved efficacy reach the purpose of preventing metastasis as well as improving the efficacy.
Pink calla lilies

Calla Health Foundation

DUKE INVENTOR: Nimmi Ramanujam

callahealthfoundation.com

Calla Health is a newly formed entity dedicated to improving the lives of women through technological innovations. Our vision is to sustainably improve access to women’s cancer prevention with a low-cost, hand-held, portable imaging devices, mHealth communication platforms, and an automated decision-making algorithm. Technologies under Calla Health are the Pocket Colposcope and the Callascope, which were developed to implement “see-and-treat” paradigms.

Calla Health logo

The Pocket Colposcope

The new instrument with the potential to revolutionize cervical cancer screening in low-resource settings.

Colposcope for detecting cervical cancer

The Callascope

Reimaginging the gynecological exam as we know it, obviating the need for the speculum and enabling users to have more autonomy over their bodies.

callscope

Lab-grown Tissue Patch Could Fix Ailing Hearts

Every 40 seconds, someone in the United States has a heart attack. Each time, up to a billion heart muscle cells suffocate. Those lost cells never regrow, leaving almost 800,000 people a year impaired for life—if they survive at all. Nenad Bursac believes he can patch some of those people up, literally.

Over the past 20 years, the bioengineer from Duke University in Durham, North Carolina, has been developing a “patch” that could take the place of the cells destroyed by a heart attack. In rodents, he has found it can hook up to the circulatory system and contract. Bursac’s patch is now about the size of a poker chip and the thickness of cardboard—big and complex enough to be tested in large animals, he declared this month at the Experimental Biology 2019 meeting in Orlando, Florida.

Like others attempting to repair damaged hearts, Bursac starts with stem cells, which can develop into specialized tissues such as heart muscle. But whereas some researchers inject hundreds of millions of individual heart muscle cells into the body, Bursac’s team and several other groups grow full-fledged pieces of heart muscle in a dish, which surgeons could attach to a damaged heart. “This could be a transformative approach,” says Ralph Marcucio, a developmental biologist at the University of California, San Francisco, School of Medicine. Bursac’s research effort “is the best in the field,” adds Martine Dunnwald, a cell biologist at the University of Iowa in Iowa City.

At one point, cardiologists thought the heart had a secret stash of stem cells that could be stimulated to repair the organ naturally, but now most biologists agree such cells don’t exist in the heart (Science, 18 July 2014, p. 252). An alternative in early clinical trials is to make heart muscle cells in a lab dish from other stem cells, inject them into the artery supplying the heart, and hope they settle in the organ and compensate for any dead tissue.

Bursac is skeptical of that approach, because the percentage of cells that survive injection and make it to the heart is very small. His approach requires open-heart surgery, but it delivers a repair that more closely matches the cell types and architecture of the real organ. “What people are now seeing is you need more structure and more cells,” says Jeffrey Jacot, a bioengineer at the University of Colorado Anschutz Medical Campus in Aurora.

Bursac started to work on heart patches as a Ph.D. student, coaxing neonatal rat cells to transform into heart muscle in a dish and contract—a first for mammals. Other researchers developed tiny heart tissue swatches for testing drugs in lab dishes. But Bursac wants to fix hearts directly. Over the years, his team has learned the best scaffolds for culturing stem cells are made of fibrin, a protein that helps form blood clots, and the best way to nurture these scaffolded cells is to gently rock them inside a suspended frame that allows the growing patch to swish back and forth in liquid media. “These cells mature and become strongly contracting,” Bursac says.

In 2016, when his lab figured out how to produce those powerful contractions, the heart patches were tiny. Then, 2 years ago, the team grew a 4-centimeter-by-4-centimeter patch—potentially big enough to repair a damaged human heart.

 

 

READ THE FULL STORY HERE

[Originally posted by Science — April 26, 2019]